Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Cancer

    • Home
    • Cancer
    • Page 139
Company Drug

Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients

Fineline Cube May 14, 2020

Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...

Posts pagination

1 … 138 139

Recent updates

  • Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages
  • Sanofi Rezurock Wins EU Backing for Graft‑Versus‑Host Disease
  • CMS-D017 Gets NMPA Nod for PNH Clinical Trial
  • J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer
  • Hengrui Ruitanning Gets NMPA Nod for Moderately Emetogenic Chemo Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages

Company Drug

Sanofi Rezurock Wins EU Backing for Graft‑Versus‑Host Disease

Company Drug

CMS-D017 Gets NMPA Nod for PNH Clinical Trial

Company Drug

J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.